ArticleJournal of medical microbiology2017
Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis.
Article in Journal of medical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.The Cochrane database of systematic reviews · 2019Pooled it
- Diagnostic value of galactomannan in tracheobronchial aspirate forJournal of clinical microbiology · 2026Article
- Article
- Diagnostic Performance of Sōna GM LFA in Pulmonary Infections Caused by Different Aspergillus Species.Mycoses · 2026Article
- Chromatin Remodeling Factor Arp8 Is Involved in the Regulation of Aflatoxin Biosynthesis and Fungal Pathogenicity ofJournal of fungi (Basel, Switzerland) · 2026Article
- The clinical value of metagenomic next generation sequencing in the diagnosis of non-neutropenic invasive pulmonary aspergillosis.Frontiers in cellular and infection microbiology · 2026Article
- Diagnostic performance ofJournal of thoracic disease · 2025Article
- Article
- Impact of Invasive Pulmonary Aspergillosis in Critically Ill Surgical Patients with or without Solid Organ Transplantation.Journal of clinical medicine · 2023Article
- Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Galactomannan-Antigen Testing from Non-Directed Bronchial Lavage for Rapid Detection of Invasive Pulmonary Aspergillosis in Critically Ill Patients: A Proof-of-Concept Study.Diagnostics (Basel, Switzerland) · 2023Article
- Long-Term Kinetics of Serum Galactomannan during Treatment of Complicated Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Review
- Allergic bronchopulmonary candidiasis: A review of the literature and a case report.BMC pulmonary medicine · 2022Review
- Recombinant polymerase amplification combined with lateral flow strips for the detection of deep-seatedFrontiers in cellular and infection microbiology · 2022Article
- Invasive Pulmonary Aspergillosis DiagnosisFrontiers in medicine · 2022Article
- The Effect ofFrontiers in pharmacology · 2021Review
- Diagnostic Accuracy of Bronchoalveolar Lavage Fluid Galactomannan for Invasive Aspergillosis.BioMed research international · 2020Article
- Multiplex PCR of bronchoalveolar lavage fluid in children enhances the rate of pathogen detection.BMC pulmonary medicine · 2019Article
- Invasive Aspergillosis byJournal of fungi (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe detection of galactomannan (GM) in bronchoalveolar lavage (BAL) fluid is an important surrogate marker for the early diagnosis and therapeutic monitoring of invasive aspergillosis (IA), regardless of the involved species of Aspergillus. Here, we utilized the Platelia Aspergillus GM enzyme immunoassay (Bio-Rad) to evaluate the GM index in BAL fluid samples from patients with proven, probable or putative IA due to Aspergillusflavus versus Aspergillusfumigatus. METHODOLOGY: In a prospective study between 2009 and 2015, 116 BAL samples were collected from suspected IA patients referred to two university hospitals in Tehran, Iran. KEY
findingsAccording to European Organization for Research and Treatment of Cancer and Mycoses Study Group and Blot criteria, 35 patients were classified as IA patients, of which 33 cases tested positive for GM above 0.5 and, among these patients, 22 had a GM index ≥1. Twenty-eight were culture positive for A. flavus and seven for A. fumigatus. The GM index for A. flavus cases was between 0.5-6.5 and those of A. fumigatus ranged from 1 to 6.5. The sensitivity and specificity of a GM index ≥0.5 in cases with A. flavus were 86 and 88 % and for A. fumigatus patients were 100 and 73 %, respectively.
conclusionOverall, the mean GM index in patients with A. fumigatus (3.1) was significantly higher than those of A. flavus (1.6; P-value=0.031) and the sensitivity of GM lower for A. flavus when compared to A. fumigatus. This finding has implications for diagnosis in hospitals and countries with a high proportion of A. flavus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.